Co-Author
This page shows the publications co-authored by Bimalangshu Dey and Joseph Antin.
Connection Strength
0.807
-
Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8.
Score: 0.127
-
Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1025-31.
Score: 0.108
-
Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007 Jan; 13(1):82-9.
Score: 0.086
-
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810.
Score: 0.052
-
Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. 2018 03; 103(3):522-530.
Score: 0.046
-
Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284.
Score: 0.043
-
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504.
Score: 0.042
-
Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant. 2016 May; 22(5):910-8.
Score: 0.040
-
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8.
Score: 0.037
-
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1374-80.
Score: 0.034
-
Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.
Score: 0.033
-
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jun; 19(6):981-7.
Score: 0.033
-
Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011 May; 46(5):659-67.
Score: 0.028
-
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9.
Score: 0.027
-
High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion. 2009 May; 49(5):995-1002.
Score: 0.025
-
Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008 Mar; 41(6):523-9.
Score: 0.023
-
Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant. 2007 Jul; 13(7):838-43.
Score: 0.022
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.